Author:
Blagova O. V.,Alijeva I. N.,Bezrukov E. A.,Ippolitov L. I.,Polunin G. V.,Kogan E. A.,Sedov V. V.,Mershina E. A.,Sinitsyn V. E.,Sarkisova N. D.,Nedostup A. V.,Fomin V. V.
Abstract
Hypertensive heart disease with biventricular cardiac failure is not common in clinical practice. This diagnosis requires an extensive diagnostic search. We present the clinical case of the male patient of 38 aged. He was admitted to the clinic with heart failure 3-4 NYHA class. EchoCG revealed symmetric hypertrophy of the left ventricle up to 18 mm without its dilatation, a decrease in ejection fraction up to 42%, restrictive hemodynamics, overload of the right chambers, severe pulmonary hypertension (60 mm Hg). The clinical status included persistent arterial hypertension (180-220 and 120-150 mm Hg), effusion in both pleural cavities and pericardium, ascites, renal failure. During examination (multispiral computed tomography, magnetic resonance imaging, scintigraphy with 131I-MIBG), bladder paraganglioma was diagnosed (normatenafrin 1468 μg/day). The resection of the tumor was performed, according to immunohistochemical research – neuroendocrine carcinoma, G1. After 3 months a partial regression of hypertension and cardiac failure was observed with the preservation of a high level of creatinine. The criteria and differential diagnosis of the hypertensive heart disease and the syndrome of primary myocardial hypertrophy, diagnostics of the urinary bladder paraganglioma, complex mechanisms of myocardial damage within the pheochromocytoma and its prognosis are discussed.
Publisher
Stolichnaya Izdatelskaya Kompaniyaizdat
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine
Reference16 articles.
1. Maron B.J., Maron M.S. A Discussion of Contemporary Nomenclature, Diagnosis, Imaging, and Management of Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2016;118(12):1897-907. doi: 10.1016/j.amjcard.2016.08.086.
2. Frustaci A., Francone M., Petrosillo N., Chimenti C. High prevalence of myocarditis in patients with hypertensive heart disease and cardiac deterioration. Eur J Heart Fail. 2013;15(3):284-91. doi: 10.1093/eurjhf/hfs169.
3. Elliott P.M., Anastasakis A., Borger M.A. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. doi: 10.1093/eurheartj/ehu284.
4. Rosmini S., Biagini E., O'Mahony C. et al. Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy. Heart. 2017;103(4):300-6. doi: 10.1136/heartjnl2016-310138.
5. Blagova O.V., Nedostup A.V., Kogan E.A. et al. The Materials of Russian national congress of cardiology "Innovations and progress in cardiology" (Kazan, September 24-26, 2014). Kazan: RCS; 2014: P. 82. (In Russ) [Благова О.В., Недоступ А.В., Коган Е.А. и др. Результаты клинико-морфологической диагностики при первичном синдроме гипертрофии миокарда. Материалы Российского национального конгресса кардиологов «Инновации и прогресс в кардиологии» (Казань, 24-26 сентября 2014 г.). Казань: РКО; 2014: С. 82].